to doses as large as 60 g/kg/day 2 of G-CSF have been with no clear consensus on the most cost-effective dose. We performed a prospective randomized trial examindescribed in the literature. There is no consensus on the most cost-effective dose of G-CSF after autologous ing the efficacy of three different doses of G-CSF postautologous transplant (5, 10, or 16 g/kg/day). Fiftyprogenitor cell transplantation. This report details results from a prospective randomized seven consecutive patients with breast cancer (n ‫؍‬ 30), non-Hodgkin's lymphoma (n ‫؍‬ 16), Hodgkin's disease trial of three commonly used doses of G-CSF (5, 10 and 16 g/kg/day) after autologous PBPC transplantation. Con-(n ‫؍‬ 6), multiple myeloma (n ‫؍‬ 2), acute leukemia (n ‫؍‬ 2), and testicular cancer (n ‫؍‬ 1) were randomized, secutive patients undergoing autologous transplantation, with a variety of diseases and prognostic variables, were with 19 patients enrolled in each of the three treatment groups. All patients underwent a high-dose chemoentered into this study to reflect clinical reality at a typical transplant center. therapy preparative regimen and received an autologous peripheral blood progenitor cell (PBPC) transplant (without bone marrow), with G-CSF beginning on day 0. There was no difference in time to neutrophil Patients and methods engraftment among the three treatment groups (mean 10.2 to 10.8 days). There is a trend towards earlier Fifty-seven consecutive patients undergoing high-dose chemotherapy with PBPC transplantation were studied platelet engraftment in the patient group receiving 5 g/kg/day of G-CSF. The total cost of G-CSF by dose from November 1994 to June 1995. All were treated on protocols approved by the Institutional Review Board of the group was $2900, $4400, and $6500 per patient. We conclude that there was no advantage to the use of higher Cleveland Clinic Foundation. Eligibility included adequate cardiac, pulmonary, hepatic, and renal function prior to doses of G-CSF after autologous transplantation, and that lower doses are associated with lower costs.
transplantation. Keywords: autologous bone marrow transplant; G-CSF; progenitor cell engraftment; peripheral blood progenitor Study schema cells
The study schema is shown in Figure 1 . Patients were prospectively randomized to receive one of three doses of G-CSF (administered intravenously over 30 min) after The time to neutrophil engraftment after autologous bone infusion of G-CSF primed peripheral blood progenitor cells marrow transplantation has dramatically improved over the (PBPC): 5 g/kg/day, 10 g/kg/day, 16 g/kg/day. The past decade. Treatment with G-CSF and/or GM-CSF after costs of G-CSF were calculated by patient charges supplied the infusion of autologous bone marrow significantly shortby the Cleveland Clinic Pharmacy. ens the duration of neutropenia, generally from approximately 3 weeks to approximately 2 weeks.
1,2 The use of PBPC mobilization growth factor primed peripheral blood progenitor cells (PBPC) further accelerates neutrophil engraftment, and also All patients received G-CSF 5 g/kg/day for PBPC mobilaccelerates platelet engraftment. [3] [4] [5] [6] [7] [8] [9] [10] [11] were harvested.
seven patients were randomized to ensure an adequate number of patients who engrafted. This analysis includes 19 patients randomized to each group. Univariate analysis for association of categorical factors with treatment group was done with a 2 test. Continuous factors, including time to engraftment, were compared with a Kruskal-Wallis test because of the non-normal nature of the factors. Spearman correlations were used to test for correlations among pairs of continuous factors. A stepwise multiple regression model was used to test the effect of treatment group after adjusting for CD34 dose. When platelet engraftment time was defined as Ͼ12 or р12 days, a multiple logistic regression model was used to test for treatment effect after adjusting for CD34 dose. A P value of 0.05 or less was considered to be statistically significant while P values less than 0.10 but grater than 0.05 were considered marginally significant. All analyses were completed using SAS software (SAS Institute Software, Cary, NC, USA).
Results
The pre-transplant characteristics of the patient population are shown in Table 1 . The three groups were balanced with respect to underlying diagnosis and prior therapy. The aver- was no significant correlation of age with engraftment. The transplant characteristics are shown in Table 2 . Despite randomization, patients receiving 16 g/kg after Transplant protocol transplantation had a slightly lower dose of CD34 ϩ cells collected than did the other two groups. All patients were transplanted with one of four chemotherapy (only) transplant regimens: cyclophosphamide, All patients successfully underwent autologous transplantation. All 57 patients survived and were evaluable for thiotepa, carboplatin (cyclophosphamide 1500 mg/m 2 /day ϫ 4 days; thiotepa 125 mg/m 2 /day ϫ 4 days; carboplatin engraftment analysis. The time to neutrophil and platelet engraftment is shown in Table 3 . Bar charts detailing the 200 mg/m 2 /day ϫ 4 days), busulfan, cyclophosphamide, VP-16 (busulfan 14 mg/kg, etoposide 50 mg/kg, cyclophosfrequency distribution for neutrophil and platelet engraftment are shown in Figures 2 and 3 . There was no phamide 120 mg/kg); ifosphamide 16 gm/m 2 ; carboplatin 1800 mg/m 2 , etoposide 1.5 gm/m 2 ; or busulfan, cyclophosdifference in the time to neutrophil engraftment between the three arms of the study. The strongest correlation of phamide (busulfan 16 mg/kg, cyclophosphamide 120 mg/kg). The G-CSF was begun 4 h after the infusion both neutrophil and platelet engraftment was the total number of CD34 ϩ cells infused (P ϭ 0.0001). A multivariate of PBPC. G-CSF was discontinued after patients reached 500 neutrophils/mm 3 on 2 consecutive days. analysis was performed which adjusted for the CD34 ϩ cell dose; this analysis found that the prolonged time to platelet engraftment seen in the 16 g/kg arm was not statistically Supportive care significant (P ϭ 0.09). However, additional analysis was performed on those patients who experienced rapid platelet Patients received prophylactic antibiotics consisting of oral ciprofloxacin, intravenous acyclovir, and low-dose engraftment as defined by engraftment in р11 days posttransplant. Twenty-eight patients in the overall group were (0.2 mg/kg) amphotericin-B. Patients experiencing persisting fevers had their antibiotic coverage broadened.
classified as rapid engrafters, 11 in the five-dose group, 12 in the 10-dose group, and 5 in the 16-dose group. MultivariPatients received transfusions of red blood cells and platelets as indicated. Generally, platelets were single donor ate-analysis revealed that the lack of rapid engrafters in the 16-dose group was significant (P ϭ 0.05) even with adjusttransfusions, administered for a platelet count Ͻ15 000 ϫ 10 6 /l or for clinical bleeding. ment for CD34 ϩ cell dose infused. Although several chemotherapeutic preparative regimens were employed, there was no significant difference in CD34 cell yield, days Statistical analysis to platelet engraftment, or days to neutrophil engraftment by preparative regimen. A sample size of 16 in each group for a total of 48 patients was needed to have a 90% power to detect a difference of Patients in all three groups received an average number of five platelet transfusions while hospitalized. There was 3 days in engraftment. A difference of 1 or 2 days in engraftment was not felt to be clinically important. Fiftyno difference in clinical bleeding between the three groups. 1 (5) 1 (5) 2 (11) NHL ϭ non-Hodgkin's lymphoma; HD ϭ Hodgkin's disease; AL ϭ acute leukemia; MM ϭ multiple myeloma; TC ϭ testicular cancer; XRT ϭ radiation therapy The patients received G-CSF for a mean number of 13.8, Spitzer et al 12 series, patients were randomized to receive either no growth factors or a combination of G-CSF 12.9, and 13.9 days in the five-, 10-, and 16-dose groups, respectively. This resulted in an average cost of G-CSF of (7.5 g/kg/day) and GM-CSF (2.5 g/kg/day). Median days to 500 neutrophils/l was 10 (in the growth factor $2900, $4400, and $6500, by treatment group. group) vs 16 days, which was highly statistically significant. Klumpp et al 13 reported a study in which patients received either G-CSF (5 g/kg/day) or no growth factor Discussion after autologous PBPC transplant. Median time to 500 neutrophils per/l was 10.5 days in the G-CSF group and 16 Most data examining the use of G-CSF after autologous transplantation employ historical control groups. Three prodays in the control group (P ϭ 0.0001). Cortelazzo et al 14 reported a study in which patients received PBPC autologspective trials were recently reported examining G-CSF vs no growth factor after autologous transplantation. In the ous transplantation with or without G-CSF (5 g/kg/day). Median time to 500 neutrophils/l was faster in the G-CSF suggestion that platelet engraftment was not as rapid when using higher doses of G-CSF. treated group (10 days vs 12 days); however, this was not a statistically significant difference. As a result of these data,
In the Spitzer et al 12 series comparing G-CSF and GM-CSF vs placebo after autologous transplantation, there was many, if not most, autologous transplant centers employ G-CSF after autologous progenitor cell transplantation. The a slightly prolonged time to platelet engraftment seen with the use of growth factors, although this did not reach stattime to neutrophil engraftment seen in our study (10.5 days) was comparable with the results cited above. istical significance. Lindemann et al 16 reported a phase I study of G-CSF in which platelet counts decrease over time Documented reports have used doses of G-CSF of 5, 5,6,8,9,11 10, 10 16, 3,7 24, 4 and 60 2 g/kg/day. Linch et al with a nadir occurring 10 days after G-CSF administration in patients with cancer (not receiving a bone marrow reported a vehicle-controlled dose-finding study of G-CSF after bone marrow transplantation. 15 This study included transplant). The number of bone marrow megakaryocytes remained unchanged. Platelets rebounded after discontinupatients undergoing autologous bone marrow (not blood progenitor cell) and allogeneic bone marrow transplanation of G-CSF and the modest decrease was not of clinical consequence. Mueller et al 17 noted a decrease in platelets tation. Patients were randomized to receive placebo or G-CSF after transplantation in doses of 2, 5, 10, and in children with HIV infection treated with G-CSF. Again, no clinical sequellae resulted from the thrombocytopenia. 20 g/kg/day. Neutrophil recovery was accelerated in a dose-dependent fashion, but the major difference was
The vast majority of reports detailing the use of G-CSF after autologous transplantation have not shown an adverse between the control group and all groups receiving G-CSF. We found that increased doses of G-CSF did not signifieffect of platelet engraftment; rather as stated above, the use of primed PBPC actually accelerates time to platelet cantly enhance the time to neutrophil engraftment as compared to a dose of 5 g/kg/day. Additionally, there is a engraftment. We do not think the apparent difference in infused as unprocessed autologous whole blood shorten the platelet engraftment by higher doses of G-CSF seen in the pancytopenic period following high-dose melphalan in multhree treatment groups in our study is clinically relevant.
tiple myeloma. Bone Marrow Transplant 1994; 13: 37-41.
Pharmacy costs are one of the most important variables
